Cargando…
Similarly efficacious anti-malarial drugs SJ733 and pyronaridine differ in their ability to remove circulating parasites in mice
BACKGROUND: Artemisinin-based combination therapy (ACT) has been a mainstay for malaria prevention and treatment. However, emergence of drug resistance has incentivised development of new drugs. Defining the kinetics with which circulating parasitized red blood cells (pRBC) are lost after drug treat...
Autores principales: | SheelaNair, Arya, Romanczuk, Aleksandra S., Aogo, Rosemary A., Haldar, Rohit Nemai, Lansink, Lianne I. M., Cromer, Deborah, Salinas, Yandira G., Guy, R. Kiplin, McCarthy, James S., Davenport, Miles P., Haque, Ashraful, Khoury, David S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8848794/ https://www.ncbi.nlm.nih.gov/pubmed/35172826 http://dx.doi.org/10.1186/s12936-022-04075-z |
Ejemplares similares
-
Plasmodium-specific antibodies block in vivo parasite growth without clearing infected red blood cells
por: Akter, Jasmin, et al.
Publicado: (2019) -
Review of pyronaridine anti-malarial properties and product characteristics
por: Croft, Simon L, et al.
Publicado: (2012) -
Combining SJ733, an oral ATP4 inhibitor of Plasmodium falciparum, with the pharmacokinetic enhancer cobicistat: An innovative approach in antimalarial drug development
por: Gaur, Aditya H., et al.
Publicado: (2022) -
Global gene expression profiling of Plasmodium falciparum in response to the anti-malarial drug pyronaridine
por: Kritsiriwuthinan, Kanyanan, et al.
Publicado: (2011) -
Plasmid-free CRISPR/Cas9 genome editing in Plasmodium falciparum confirms mutations conferring resistance to the dihydroisoquinolone clinical candidate SJ733
por: Crawford, Emily D., et al.
Publicado: (2017)